Quick-Med Technologies, Inc. Resolves Dispute With
Cosmetics Distribution Partner

Gainesville, Florida – September 7, 2006 – Quick-Med Technologies, Inc. (OTC BB: QMDT) (“QMT”, the “Company”) announced that it has resolved a contract dispute with its cosmetics distribution partner Engelhard Long Island, Inc.  (“Engelhard”), a wholly owned subsidiary of Engelhard Corporation, which manufactures and distributes cosmetic ingredients using the Company’s MultiStat™ technology.    The terms of the new agreement have been codified in a Letter of Intent (“LOI”) and a related term sheet that contain binding financial terms through August 1, 2007 and provide for a continuation of the agreement for up to 3 years.  The LOI amends the Master Agreement for Product Development, Manufacturing and Distribution (the “Master Agreement”), which was entered into by the parties on August 15, 2002.

Under the agreement, as amended by the LOI, the Company granted to Engelhard an exclusive license to develop and market the Company’s MultiStat technology for the field of over-the-counter anti-aging cosmetics. The parties may separately enter a non-exclusive license for the field of over-the-counter acne treatments and skin moisturizers in the cosmetic market. These agreements substantially reduce the end-market scope of the agreement with Engelhard, allowing the Company to pursue other opportunities with its technology. In consideration for this license, the Company will receive monthly royalty payments of approximately 40% of the net revenue that Engelhard receives from sales of the MultiStat-based products, with minimum royalty payments totaling  $1,140,000 for the first two years assuming the agreement is not terminated during such period.  In addition, the LOI amended the Master Agreement to transfer back to Engelhard certain intellectual property developed by Engelhard for the Company in exchange for one lump-sum payment of $166,500.

Engelhard is currently distributing anti-aging products using the Company’s technology to such firms as Bath and Body Works (a division of Limited Brands, Inc.) under the Patricia Wexler M.D. cosmetic skincare product line, and Elizabeth Arden, Inc., under the Ceramide Plump Perfect cosmetic skincare product line. For the 12 months ended July 31 2006, the Company has realized approximately $1.25 million in revenue through its partnership with Engelhard.

On June 12, 2006, BASF Aktiengesellschaft (“BASF”) announced the completion of its acquisition of Engelhard Corporation. As a result of the transaction, Engelhard Corporation is a wholly owned subsidiary of BASF, and its shares no longer trade on the New York Stock Exchange.

Additional information can be found in the Company's current report on Form 8-K and 10-KSB for the fiscal year ended June 30, 2005 filed with the Securities and Exchange Commission.

About Quick-Med Technologies, Inc.
Quick-Med Technologies is a life sciences company focused in developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company¹s two core products under development are (1) MultiStat™, a family of advanced compounds shown to be effective in broad-based skin therapy applications, and (2) NIMBUS™, a family of advanced polymers that can be used in a wide range of applications from advanced wound care to wood preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies¹ website: www.quickmedtech.com or email: info@quickmed-technologies.com

For additional further information, please contact QMT:

David S. Lerner -- President
Phone : (561) 750-4202
Email: dlerner@quickmed-technologies.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.